UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/519,805	12/13/2005	Brad St. Croix	001107.00527	7620
22907 7590 03/18/2008 BANNER & WITCOFF, LTD. 1100 13th STREET, N.W.			EXAMINER	
			NATARAJAN, MEERA	
SUITE 1200 WASHINGTO	N, DC 20005-4051		ART UNIT	PAPER NUMBER
			1643	
			MAIL DATE	DELIVERY MODE
			03/18/2008	PAPER

# Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)
	10/519,805	ST. CROIX ET AL.
Office Action Summary	Examiner	Art Unit
	MEERA NATARAJAN	1643
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA  - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period w  - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 6(a). In no event, however, may a reply be time fill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).
Status		
<ul> <li>1) Responsive to communication(s) filed on 25 Ja</li> <li>2a) This action is FINAL. 2b) This</li> <li>3) Since this application is in condition for allowant closed in accordance with the practice under E</li> </ul>	action is non-final. nce except for formal matters, pro	
Disposition of Claims		
4) ☐ Claim(s) 1-25 is/are pending in the application. 4a) Of the above claim(s) 1-22 and 25 is/are wit 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) 23 and 24 is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) are subject to restriction and/or Application Papers 9) ☐ The specification is objected to by the Examiner 10) ☐ The drawing(s) filed on is/are: a) ☐ access	election requirement.	≣xaminer.
Applicant may not request that any objection to the c Replacement drawing sheet(s) including the correcti	on is required if the drawing(s) is obj	jected to. See 37 CFR 1.121(d).
11)☐ The oath or declaration is objected to by the Ex	aminer. Note the attached Office	Action or form PTO-152.
Priority under 35 U.S.C. § 119		
12) ☐ Acknowledgment is made of a claim for foreign     a) ☐ All b) ☐ Some * c) ☐ None of:     1. ☐ Certified copies of the priority documents     2. ☐ Certified copies of the priority documents     3. ☐ Copies of the certified copies of the prior application from the International Bureau * See the attached detailed Office action for a list of	s have been received. s have been received in Applicati ity documents have been receive (PCT Rule 17.2(a)).	on No ed in this National Stage
Attachment(s)  1) Notice of References Cited (PTO-892)  2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  3) Information Disclosure Statement(s) (PTO/SB/08)  Paper No(s)/Mail Date 06/05/2006 and 06/22/2006.	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:	ate

Application/Control Number: 10/519,805 Page 2

Art Unit: 1643

### **DETAILED ACTION**

### Election/Restrictions

1. Applicant's election with traverse of Group XII, Claims 23 and 24 and species election "secreted protein, acidic, cysteine-rich osteonectin" in the reply filed on 01/25/2008 is acknowledged. The traversal is on the ground(s) that Applicant's believe groups XII and III should be examined together and would not present an undue search burden if the groups were rejoined. This is not found persuasive because the test sample and reagents used in the two groups are different and the outcomes of the methods (identifying neoangiogenesis or identifying endothelial cells) are different (as pointed out by the applicant in their response). The requirement is still deemed proper and is therefore made FINAL.

- 2. Claims 1-22 and 25 withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to nonelected inventions, there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in the reply filed on 01/25/2008.
- 3. Claims 23 and 24 will be examined on the merits.

## Claim Rejections - 35 USC § 102

4. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States

Application/Control Number: 10/519,805 Page 3

Art Unit: 1643

only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

- 5. Claims 23 and 24 are rejected under 35 U.S.C. 102(e) as being anticipated by Long et al. (PgPub 20040214241).
- 6. The Claims are drawn to a method of identifying endothelial cells, comprising contacting a population of cells with one or more antibodies which bind specifically to osteonectin, detecting cells in the population which have bound to said antibody, and identifying cells which are bound to said antibody as endothelial cells and further comprising isolating cells which have bound to said antibody.
- 7. Long et al. teach a method of isolating, purifying and characterizing precursors to osteoblasts. Long et al. disclose a method of obtaining a population of cells, contacting said cells with an antibody, and removing cells of the population that do not immunoreact with said antibody (See sections [0035-0038]). Claims 16 and 18-20 of Long et al. disclose the use of an osteonectin antibody to isolate osteoblasts. Long et al. teach the active steps of contacting a population of cells with an osteonectin antibody, detecting the cells which have bound to said antibody, and isolating cells which have bound to said antibody. Therefore, Long et al. inherently teach a method of identifying endothelial cells by performing the active steps of the method claimed in the instant application.

#### Conclusion

- 8. Claims 23 and 24 are rejected.
- 9. No Claims are allowed.

Application/Control Number: 10/519,805 Page 4

Art Unit: 1643

10. Any inquiry concerning this communication or earlier communications from the

examiner should be directed to MEERA NATARAJAN whose telephone number is

(571)270-3058. The examiner can normally be reached on Monday-Thursday, 9:30AM-

7:00PM, ALT. Friday. EST.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Larry Helms can be reached on 571-272-0832. The fax phone number for

the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the

Patent Application Information Retrieval (PAIR) system. Status information for

published applications may be obtained from either Private PAIR or Public PAIR.

Status information for unpublished applications is available through Private PAIR only.

For more information about the PAIR system, see http://pair-direct.uspto.gov. Should

you have questions on access to the Private PAIR system, contact the Electronic

Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a

USPTO Customer Service Representative or access to the automated information

system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

MN

/Larry R. Helms/

Supervisory Patent Examiner, Art Unit 1643